Novel strategy to selectively target tumor cell growth and chemosensitivity

选择性靶向肿瘤细胞生长和化疗敏感性的新策略

• 批准号: 267149
• 负责人: Batist Gerald
• 金额: $ 55.93万
• 依托单位: Lady Davis Institute for Medical Research (Mtl)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-09-01 至 2017-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=267149&lang=en
• 关键词: Keap1; P13kinase; Selective Chemosensitization; Therapeutic Resistance; Transcriptional Protein Nrff2

The greatest threat to cancer patients is resistance of tumors to treatment. Overcoming resistance will have a major impact on survival. We are studying a system that cells use to protect themselves from damage. Tumors use this system to become resistant,

癌症患者面临的最大威胁是肿瘤对治疗的耐药性。克服抵抗力将对生存产生重大影响。我们正在研究一种细胞用来保护自己免受伤害的系统。肿瘤利用这个系统产生抗药性，